Orexin
Sleep / WakefulnessAlso known as: Orexin-A, Orexin-B, Hypocretin-1, Hypocretin-2
Mechanism
Neuropeptides produced in the hypothalamus that control wakefulness, appetite, and reward. Loss of orexin-producing neurons is what causes narcolepsy. Drugs that block orexin receptors (suvorexant/Belsomra, lemborexant/Dayvigo) are FDA-approved sleep aids that work differently from traditional sedatives — they turn off the wakefulness signal rather than forcing sedation. Orexin agonists are being developed to treat narcolepsy.
Technical detail
Two neuropeptides — Orexin-A (33 aa, two disulfide bonds, pyroglutamyl N-terminus) and Orexin-B (28 aa, linear) — cleaved from prepro-orexin (131 aa). Produced exclusively by ~70,000 neurons in the lateral hypothalamus. Signal through OX1R (Gq-coupled, selective for Orexin-A) and OX2R (Gq-coupled, nonselective). Wakefulness: orexin neurons project to all monoaminergic wake centers (locus coeruleus/NE, raphe/5-HT, TMN/histamine, VTA/DA) and cholinergic nuclei, stabilizing the wake state. Narcolepsy type 1: autoimmune destruction of orexin neurons (undetectable CSF orexin-A, <110 pg/mL). Dual orexin receptor antagonists (DORAs): suvorexant (Belsomra, FDA 2014), lemborexant (Dayvigo, FDA 2019). OX2R-selective antagonist: seltorexant (Phase 3 for insomnia/MDD). Orexin agonists: TAK-994 (Takeda, discontinued due to safety), danavorexton (Phase 2 for narcolepsy type 1).
Effects
## Central Nervous System — Wakefulness and Arousal [Tier 1 — Extensive Human Data] Orexin (also called hypocretin) refers to two neuropeptides — Orexin-A (OX-A, 33 amino acids) and Orexin-B (OX-B, 28 amino acids) — produced exclusively by a small cluster of ~70,000 neurons in the lateral hypothalamus. They act on two G-protein coupled receptors: OX1R (selective for OX-A) and OX2R (responsive to both OX-A and OX-B). The orexin system is the MASTER SWITCH for the sleep-wake transition. Orexin neurons fire during wakefulness, activate arousal centers throughout the brain (locus coeruleus/norepinephrine, tuberomammillary nucleus/histamine, dorsal raphe/serotonin, ventral tegmental area/dopamine, basal forebrain/acetylcholine), and are silent during sleep. Loss of orexin neurons causes narcolepsy type 1 — the most dramatic evidence for their essential role. ## Sleep-Wake Regulation — The Flip-Flop Switch [Tier 1 — Established Neuroscience] The orexin system stabilizes the "flip-flop switch" between wakefulness and sleep (Saper et al., Neuron 2001). Without orexin, the brain oscillates unstably between wake and sleep states — this is why narcolepsy patients have both involuntary sleep attacks during the day AND fragmented nighttime sleep. Orexin acts like a finger pressing down on one side of a light switch, keeping it locked in the "on" (wake) position during the day. ## Metabolic System — Energy Homeostasis [Tier 2 — Moderate Human Data] Orexin neurons integrate metabolic signals (glucose, leptin, ghrelin) with arousal state. Low glucose and high ghrelin activate orexin neurons, linking hunger to wakefulness (an evolutionarily adaptive "stay awake to find food" response). Leptin inhibits orexin neurons. Narcolepsy type 1 patients have increased BMI and higher rates of type 2 diabetes, suggesting orexin loss disrupts metabolic regulation beyond sleep. ## Reward and Motivation [Tier 2 — Human and Animal Data] Orexin neurons project heavily to the ventral tegmental area (VTA) and nucleus accumbens — the dopaminergic reward circuitry. Orexin signaling is involved in motivation, reward-seeking behavior, and addiction. Orexin antagonists reduce drug-seeking behavior in animal models. This has implications for understanding the comorbidity of narcolepsy with mood disorders and reduced motivation. ## Autonomic Nervous System [Tier 2 — Human Data] Orexin promotes sympathetic tone. Narcolepsy patients have reduced sympathetic activation and lower blood pressure. Cataplexy (sudden muscle weakness triggered by strong emotions in narcolepsy) involves sudden withdrawal of orexin-mediated sympathetic and motor tone.
Practitioner Guide
## The Orexin System and Narcolepsy ### Narcolepsy Type 1 — The Orexin Deficiency Disease Narcolepsy type 1 (NT1, formerly narcolepsy with cataplexy) is caused by autoimmune destruction of orexin-producing neurons in the lateral hypothalamus. By the time of diagnosis, >90% of orexin neurons are lost, and CSF orexin-A levels are undetectable (<110 pg/mL; normal >200 pg/mL). This discovery (Nishino et al., Lancet 2000; Thannickal et al., Nat Med 2000) was one of the most important breakthroughs in sleep medicine. **Diagnostic criteria (ICSD-3):** - Excessive daytime sleepiness + cataplexy, OR - CSF orexin-A <110 pg/mL, OR - Mean sleep latency ≤8 min + ≥2 SOREMPs on MSLT ### Narcolepsy Type 2 — Normal Orexin Narcolepsy type 2 (NT2, without cataplexy) has normal CSF orexin-A levels. The pathophysiology is less clear — possibly partial orexin neuron loss or downstream receptor dysfunction. ### Orexin-Targeted Therapies **Orexin Receptor Antagonists (DORAs) — For Insomnia:** These BLOCK orexin signaling, promoting sleep: - **Suvorexant (Belsomra)** — Dual OX1R/OX2R antagonist. 10-20mg at bedtime. FDA-approved 2014. Promotes sleep WITHOUT suppressing delta waves (unlike benzodiazepines). Maintains normal sleep architecture. - **Lemborexant (Dayvigo)** — Dual OX1R/OX2R antagonist. 5-10mg at bedtime. FDA-approved 2019. Possibly more selective kinetics (faster offset → less morning drowsiness). - **Key advantage over Z-drugs:** DORAs preserve sleep architecture (delta waves, REM) while reducing time to sleep onset and increasing total sleep time. They do NOT cause the EEG changes seen with GABAergic drugs. **Orexin Replacement — For Narcolepsy (Future):** - **Orexin-A intranasal:** Preclinical and early clinical studies exploring intranasal orexin-A delivery to replace the missing neuropeptide in narcolepsy. Small human studies (Weinhold et al., 2014) showed improved wakefulness in narcolepsy patients after intranasal orexin-A. - **OX2R-selective agonists:** Under development (Takeda TAK-861, Phase II results positive in 2023). An OX2R agonist would more precisely target the wake-promoting circuit without affecting reward/autonomic pathways as strongly. - **Orexin neuron transplantation/regeneration:** Highly experimental — stem cell approaches under preclinical investigation. ### Integrating Orexin Understanding Into Sleep Optimization **For Practitioners Managing Sleep Complaints:** 1. **Insomnia with preserved sleep architecture concerns:** Consider DORAs (suvorexant, lemborexant) over benzodiazepines/Z-drugs. DORAs block the wake signal (orexin) rather than artificially boosting the sleep signal (GABA). Result: more physiological sleep. 2. **Non-refreshing sleep despite adequate duration:** The problem may be insufficient delta waves (see DSIP above). DORAs do not specifically enhance delta power — they promote consolidated sleep. DSIP + DORA could theoretically combine sleep consolidation (DORA) with delta enhancement (DSIP), though this combination has not been studied. 3. **Excessive daytime sleepiness with suspected narcolepsy:** Check CSF orexin-A levels. Low levels (<110 pg/mL) are diagnostic for narcolepsy type 1 and have essentially 100% specificity. This test is underutilized. 4. **The DSIP-Orexin Connection for Comprehensive Sleep Protocol:** - **DSIP** enhances delta waves (sleep DEPTH) through non-GABAergic, non-orexin pathways - **Orexin antagonists (DORAs)** promote sleep CONSOLIDATION by blocking the wake signal - **Melatonin** entrains circadian TIMING - **These three systems are complementary:** timing (melatonin) → consolidation (orexin blockade) → depth (DSIP) - A comprehensive sleep optimization protocol might address all three: low-dose melatonin at consistent time for circadian anchor, DORA for consolidation if needed, and DSIP for delta enhancement if non-refreshing sleep persists. 5. **Understanding the wake side:** Patients who are excessively sleepy with normal orexin may have downstream issues (post-synaptic receptor downregulation, monoamine deficiency). Traditional stimulants (modafinil, amphetamines) and solriamfetol (a NE/DA reuptake inhibitor) work downstream of orexin.
Research Summary
## Tier 1 — Strong Clinical Evidence - Orexin/hypocretin system discovery and its role in narcolepsy is one of the landmark findings in neuroscience (de Lecea et al., PNAS 1998; Sakurai et al., Cell 1998; Nishino et al., Lancet 2000) - CSF orexin-A measurement is a validated diagnostic biomarker for narcolepsy type 1 (sensitivity >95%, specificity ~100%) - Dual orexin receptor antagonists (DORAs) FDA-approved for insomnia: suvorexant (2014), lemborexant (2019) — Phase III trials showing improved sleep onset, maintenance, and preserved architecture - Narcolepsy type 1 autoimmune etiology established (HLA-DQB1*06:02 association, T-cell mediated orexin neuron destruction) ## Tier 2 — Moderate Evidence - Orexin system involvement in energy homeostasis, obesity, and metabolic syndrome (narcolepsy patients have 2-3x obesity rates) - Orexin involvement in reward circuitry and addiction (preclinical data strong, human data emerging) - Intranasal orexin-A improved wakefulness in narcolepsy patients in small proof-of-concept study (Weinhold et al., Ann Neurol 2014) - OX2R-selective agonists (TAK-861) showed positive Phase II results for narcolepsy (Takeda, 2023) - DORAs preserve sleep architecture (delta waves, REM) better than benzodiazepines/Z-drugs — confirmed in polysomnographic studies ## Tier 3 — Preclinical/Theoretical - Orexin neuron transplantation as a cure for narcolepsy (stem cell-derived orexin neurons survive and function in rodent brains) - Orexin system as a target for appetite/weight regulation beyond narcolepsy - Partial orexin deficiency as a contributor to idiopathic hypersomnia and "subclinical narcolepsy" - Orexin-based therapies for disorders of consciousness (traumatic brain injury, post-anesthesia recovery) - Selective OX1R antagonists for addiction treatment without sleep disruption